AI biotech Antiverse raised a $9.3 million Series A round to advance its antibody pipeline, CEO Murat Tunaboylu exclusively tells Axios Pro.
Why it matters: Pharma's race to de-risk early-stage drug development is fueling a surge in AI-driven startups capable of tackling complex targets like G protein-coupled receptors.
